fda warning letters compounded semaglutide tirzepatide 2024 2025 takes aim at misleading claims for GLP-1 drugs FDA issued 25 warning letters

Never change your dosage without professional guidance, as this could affect both your treatment outcomes and overall health

This dual-action makes Mounjaro slightly more effective than Ozempic (Wegovy)

The effectiveness of these medications remains proven, but insurance providers show reservations when approving their use for patients with obesity rather than type 2 diabetes 21

Patients with obesity who were treated with elafibranor had reduced levels of liver enzymes and improved insulin sensitivity114

Secondary 2026 commentary estimates possible MHRA approval in late 2027 or 2028 [1][2] [unverified, not a Lilly primary statement]